ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.480,89
0,21%
S&P 500
5.187,67
0,00%
US Dollar vs BRL
5,0909
0,03%
Bitcoin
61.100,36
-0,14%
Brent Oil
83,865
0,37%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Biogen Inc (BIIB)

  7. Biogen Inc (BIIB) Notícias

BIIB

Biogen (BIIB)

Biogen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BIIB
DataHoraFonteTítuloCódigoCompanhia
02/05/202408:30GlobeNewswire Inc.Biogen Reports Progress on Corporate Responsibility PrioritiesNASDAQ:BIIBBiogen Inc
31/03/202420:30PR Newswire (US)Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDANASDAQ:BIIBBiogen Inc
06/03/202409:30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:BIIBBiogen Inc
04/03/202418:15GlobeNewswire Inc.Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual MeetingNASDAQ:BIIBBiogen Inc
26/02/202421:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
23/02/202409:00GlobeNewswire Inc.Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPNASDAQ:BIIBBiogen Inc
22/02/202412:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
13/02/202409:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
12/02/202421:11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BIIBBiogen Inc
12/02/202418:06GlobeNewswire Inc.Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s AtaxiaNASDAQ:BIIBBiogen Inc
09/01/202419:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
19/12/202309:30GlobeNewswire Inc.Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European CommissionNASDAQ:BIIBBiogen Inc
15/12/202311:05GlobeNewswire Inc.CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative DiseaseNASDAQ:BIIBBiogen Inc
14/12/202308:30Business WireZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.NASDAQ:BIIBBiogen Inc
08/11/202318:35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BIIBBiogen Inc
08/11/202310:19IH Market NewsKeep An Eye Out: Pre-Market Movers And Analyst RecommendationsNASDAQ:BIIBBiogen Inc
06/11/202319:44KR Market News월스트리트 상승, 시장은 연준 연사 및 재무부 경매 주목NASDAQ:BIIBBiogen Inc
06/11/202309:30GlobeNewswire Inc.Biogen Appoints Monish Patolawala to its Board of DirectorsNASDAQ:BIIBBiogen Inc
26/10/202308:08IH Market NewsThursday’s Wall Street Highlights: Ford, Morgan Stanley, Align Technology, Endeavor, and moreNASDAQ:BIIBBiogen Inc
25/10/202318:26GlobeNewswire Inc.Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On AlzNASDAQ:BIIBBiogen Inc
25/10/202318:25PR Newswire (US)EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHENASDAQ:BIIBBiogen Inc
25/10/202311:51GlobeNewswire Inc.New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s DiseaseNASDAQ:BIIBBiogen Inc
24/10/202310:30PR Newswire (US)LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023NASDAQ:BIIBBiogen Inc
19/10/202308:30GlobeNewswire Inc.Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 MeetingNASDAQ:BIIBBiogen Inc
04/10/202309:15IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:BIIBBiogen Inc
29/09/202317:49Dow Jones NewsBiogen's Tofidence Intravenous Formulation Gets FDA ApprovalNASDAQ:BIIBBiogen Inc
29/09/202317:06GlobeNewswire Inc.FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®NASDAQ:BIIBBiogen Inc
28/09/202318:25Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:BIIBBiogen Inc
26/09/202309:59GlobeNewswire Inc.Biogen Completes Acquisition of Reata PharmaceuticalsNASDAQ:BIIBBiogen Inc
25/09/202302:02GlobeNewswire Inc.LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in JapanNASDAQ:BIIBBiogen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BIIB

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
OIBR3
OI ON
BOV
VVEO3
CM Hospitalar ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
JHSF3
JHSF PART ON
BOV
BRKM5
BRASKEM PNA
BOV
PRIO3
PETRORIO ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
ENAT3
ENAUTA ON
BOV
SGPS3
SPRINGS ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados